Send us Fan Mail Can a lab run cytology fully digital, with AI, and still keep rescans near 1%? CorePlus in Puerto Rico has been reading histology digitally since January 1, 2020. Then they took on the hard part: digital cytology. In this talk from the Epredia breakfast workshop at PathVisions 2026, CorePlus founder Mariano de Socarraz walks through six years of building one scanner platform for histology, Pap smears and low-cellularity urine cytology, and where AI paid off. Every AI project in pathology has to pay off three times: for the pathologist, for the business, and for the patient. You'll learn: Why CorePlus went digital on vision and gut feeling, not an ROI spreadsheet, and what "return on innovation" meansHow a prostate AI moved from second read to front-end triage: 99.2% negative predictive value across 9,300+ prostate cases and about 122,000 slidesWhy cytology is harder to scan than histology, and how water immersion scanning cut scan time by 66%How 100% Pap smear QC fits in the time a manual 10% review used to take, and the 245 cases it caughtWhy Mariano calls the 10% review standard "an illusion" (England's NHS has required 100% review since 2003)Urine cytology with AI: 92.5% sensitivity, 98.4% specificity, quantitative N:C ratios, and the fight to bring rescans down from 12%What pathology residents should learn now, and his advice for labs that haven't started Episode Highlights 00:00 - Every AI project has to pay off three times01:15 - Six years of digital pathology at CorePlus02:31 - Starting with vision, not ROI02:57 - Decoupling the pathologist from the glass04:06 - Goals: one scanner platform, redundancy, rescans below 1%07:25 - Prostate AI as a second read: 99.2% negative predictive value09:13 - AI triage on the front end10:12 - Five AI algorithms in routine use10:46 - Why cytology is harder to scan: single layer, extended focus, Z-stacking14:14 - Water immersion cuts scan time by 66%14:41 - 100% Pap smear quality control22:32 - "10% review is an illusion"23:06 - Low-cellularity urine cytology24:28 - 92.5% sensitivity, 98.4% specificity25:41 - From qualitative to quantitative: N:C ratios28:49 - Rescan rates: where they still are32:06 - Takeaways: go digital first, add AI where volume and variability are highest35:53 - Q&A: what should pathology residents learn?40:56 - Return on innovation43:34 - Advice for labs just starting CorePlus publications discussed Rivera Rolon MDM, Gustafson E, Cole R, et al., de Socarraz M, Santa-Rosario JC. Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView System. Cancer Cytopathology, 2025. doi:10.1002/cncy.70019Santa-Rosario JC, Gustafson EA, Sanabria Bellassai DE, Gustafson PE, de Socarraz M. Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosis - real-world experience. Journal of Pathology Informatics, 2024. doi:10.1016/j.jpi.2024.100378 Resources Mentioned Free Digital Pathology 101 book: https://www.aleksandrazuraw.com/bookPathology Visions 2026: https://digitalpathologyassociation.org/pathology-visions-conference This episode is sponsored by Epredia. Thank you for learning with me, trailblazer. If this helped, share it with one colleague in cytology. #DigitalPathology #DigitalCytology #PathologyAI #PathVisions2026 Support the show Get the "Digital Pathology 101" FREE E-book and join us!